These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21829040)

  • 1. Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer.
    Lorusso D; Mainenti S; Pietragalla A; Fusco E; Malaguti P; Masciullo V; Scambia G
    Oncology; 2011; 80(5-6):390-4. PubMed ID: 21829040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
    Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
    Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
    Gatcliffe TA; Tewari KS; Shah A; Brewster WR; Burger RA; Kuo JV; Monk BJ
    Gynecol Oncol; 2009 Jan; 112(1):85-9. PubMed ID: 18977518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
    Levy T; Inbar M; Menczer J; Grisaru D; Glezerman M; Safra T
    Gynecol Oncol; 2004 Dec; 95(3):686-90. PubMed ID: 15581982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma.
    Tiersten AD; Selleck MJ; Hershman DL; Smith D; Resnik EE; Troxel AB; Brafman LB; Shriberg L
    Gynecol Oncol; 2004 Feb; 92(2):635-8. PubMed ID: 14766258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topotecan concomitant with primary brachytherapy radiation in patients with cervical carcinoma: a phase I trial.
    Bell MC; Davidson SA; Mathis JM; Ampil F
    Gynecol Oncol; 2001 Feb; 80(2):128-31. PubMed ID: 11161849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group.
    Bookman MA; Blessing JA; Hanjani P; Herzog TJ; Andersen WA
    Gynecol Oncol; 2000 Jun; 77(3):446-9. PubMed ID: 10831357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study.
    Muderspach LI; Blessing JA; Levenback C; Moore JL
    Gynecol Oncol; 2001 May; 81(2):213-5. PubMed ID: 11354055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study.
    Fiorica JV; Blessing JA; Puneky LV; Secord AA; Hoffman JS; Yamada SD; Buekers TE; Bell J; Schilder JM;
    Gynecol Oncol; 2009 Nov; 115(2):285-9. PubMed ID: 19726073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
    Herzog TJ; Powell MA; Rader JS; Gibb R; Mutch DG
    Gynecol Oncol; 2006 Nov; 103(2):637-41. PubMed ID: 16781766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.
    Miller DS; Blessing JA; Lentz SS; McMeekin DS
    Cancer; 2003 Oct; 98(8):1664-9. PubMed ID: 14534883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric study.
    Zanaboni F; Grijuela B; Giudici S; Cormio G; Babilonti L; Ghezzi F; Giorda G; Scambia G; Franchi M; Lorusso M; Ditto A; Lorusso D; Raspagliesi F
    Eur J Cancer; 2013 Mar; 49(5):1065-72. PubMed ID: 23151423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
    Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy.
    Spannuth WA; Leath CA; Huh WK; Barnes MN; Davidson SA; Kilgore LC; Partridge EE; Austin JM; Alvarez RD
    Gynecol Oncol; 2007 Mar; 104(3):591-5. PubMed ID: 17045635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature.
    Traina TA; Sabbatini P; Aghajanian C; Dupont J
    Gynecol Oncol; 2004 Oct; 95(1):235-41. PubMed ID: 15385138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.
    Safra T; Menczer J; Bernstein R; Shpigel S; Inbar MJ; Grisaru D; Golan A; Levy T
    Gynecol Oncol; 2007 Apr; 105(1):205-10. PubMed ID: 17239430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
    Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
    Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.
    Stathopoulos GP; Malamos NA; Aravantinos G; Rigatos S; Christodoulou Ch; Stathopoulos J; Skarlos D
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):123-8. PubMed ID: 17111119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.